The novel p.Gly306Asp perforin mutation causes familial hemophagocytic lymphohistiocytosis type 2 (FHL-2) probably due to a critical role of Gly306 in the pore-forming perforin domain
Abstract
Background: Three substitutions at either Gly305 or Gly306 within the membrane attack/complex perforin domain (MACPF) of perforin have been previously identified in a number of patients with hemophagocytic lymphohistiocytosis (HLH). However, their pathogenic impact remains unclear since all the cases reported so far carried heterozygous genotypes and showed very heterogeneous clinical presentations. Here, we report a new substitution (p.Gly306Asp) and use in silico tools to elucidate the pathogenic mechanisms and severity associated with human Gly306 and Gly305 mutations.
Methods: The immunological workup included perforin expression and perforin gene (PRF1) mutation analysis. Computer algorithms based on conservation, secondary, and tertiary protein structure analyses were applied to assess the role of the mutations in disease pathogenesis.
Results: In our patient, we found a previously undescribed homozygous c. 917G>A (p.Gly306Asp) mutation in the PRF1 gene that was associated with null perforin expression in her natural killer lymphocytes. Sequence alignments revealed that Gly306 and Gly305 are highly conserved positions among vertebrate perforins, as well as in other related pore-forming proteins such as bacterial cytolysins. Further in silico analyses consistently predicted mutations in these 2 positions to be pathogenic due to diminished stability of the perforin molecule.
Conclusion: Age of HLH onset, severity of the disease and undetectable perforin in our p.Gly306Asp homozygous patient along with the in silico results unmask this novel mutation as highly detrimental. Our results highlight the need of combining all clinical features, in vitro phenotypes and computer based approaches to classify human perforin mutations accurately.
Statement of novelty: The study of these PRF1 mutations points to an important role of the 2 glycine amino acids (Gly305 and Gly306) in the molecular stability of perforin, which may also be likely in other pore-forming proteins. Our in silico results conclude that the pathogenicity of mutations in highly conserved Gly305 and Gly306 is likely to be associated with a serious destabilization of the native perforin conformation.
Formats available
You can view the full content in the following formats:
REFERENCES
Abdalgani M., Filipovich A.H., Choo S., Zhang K., Gifford C., Villanueva J., Bleesing J.J., and Marsh R.A. 2015. Accuracy of flow cytometric perforin screening for detecting patients with FHL due to PRF1 mutations. Blood. 126(15):1858–1860.
Adzhubei I.A., Schmidt S., Peshkin L., Ramensky V.E., Gerasimova A., Bork P., Kondrashov A.S., and Sunyaev S.R. 2010. A method and server for predicting damaging missense mutations. Nat. Methods. 7(4):248–249.
An O., Gursoy A., Gurgey A., and Keskin O. 2013. Structural and functional analysis of perforin mutations in association with clinical data of familial hemophagocytic lymphohistiocytosis type 2 (FHL2) patients. Protein Sci. 22(6):823–839.
Arico M., Allen M., Brusa S., Clementi R., Pende D., Maccario R., Moretta L., and Danesino C. 2002. Haemophagocytic lymphohistiocytosis: Proposal of a diagnostic algorithm based on perforin expression. Br. J. Haematol. 119(1):180–188.
Baran K., Dunstone M., Chia J., Ciccone A., Browne K.A., Clarke C.J., Lukoyanova N., Saibil H., Whisstock J.C., Voskoboinik I., and Trapani J.A. 2009. The molecular basis for perforin oligomerization and transmembrane pore assembly. Immunity. 30(5):684–695.
Barmettler, S., Nowak, R.J., Parker, T., and Price, C. 2016. Previously undiagnosed fatal familial haemophagocytic lymphohistiocytosis in a 24-year-old woman. BMJ Case Rep. 2016.
Barroso S., Lopez-Trascasa M., Merino D., Alvarez A.J., Nunez-Roldan A., and Sanchez B. 2010. C7 deficiency and meningococcal infection susceptibility in two spanish families. Scand. J. Immunol. 72(1):38–43.
Barroso S., Sanchez B., Alvarez A.J., Lopez-Trascasa M., Lanuza A., Luque R., Wichmann I., and Nunez-Roldan A. 2004. Complement component C7 deficiency in two Spanish families. Immunology. 113(4):518–523.
Bryceson Y.T., Pende D., Maul-Pavicic A., Gilmour K.C., Ufheil H., Vraetz T., Chiang S.C., Marcenaro S., Meazza R., Bondzio I., Walshe D., Janka G., Lehmberg K., Beutel K., zur Stadt U., Binder N., Arico M., Moretta L., Henter J.I., and Ehl S. 2012. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood. 119(12):2754–2763.
Casadio R., Vassura M., Tiwari S., Fariselli P., and Luigi Martelli P. 2011. Correlating disease-related mutations to their effect on protein stability: A large-scale analysis of the human proteome. Hum. Mutat. 32(10):1161–1170.
Chia J., Yeo K.P., Whisstock J.C., Dunstone M.A., Trapani J.A., and Voskoboinik I. 2009. Temperature sensitivity of human perforin mutants unmasks subtotal loss of cytotoxicity, delayed FHL, and a predisposition to cancer. Proc. Natl. Acad. Sci. USA. 106(24):9809–9814.
Clementi R., Emmi L., Maccario R., Liotta F., Moretta L., Danesino C., and Arico M. 2002. Adult onset and atypical presentation of hemophagocytic lymphohistiocytosis in siblings carrying PRF1 mutations. Blood. 100(6):2266.
Clementi R., Locatelli F., Dupre L., Garaventa A., Emmi L., Bregni M., Cefalo G., Moretta A., Danesino C., Comis M., Pession A., Ramenghi U., Maccario R., Arico M., and Roncarolo M.G. 2005. A proportion of patients with lymphoma may harbor mutations of the perforin gene. Blood. 105(11):4424–4428.
Dehouck Y., Grosfils A., Folch B., Gilis D., Bogaerts P., and Rooman M. 2009. Fast and accurate predictions of protein stability changes upon mutations using statistical potentials and neural networks: PoPMuSiC-2.0. Bioinformatics. 25(19):2537–2543.
Dias C., McDonald A., Sincan M., Rupps R., Markello T., Salvarinova R., Santos R.F., Menghrajani K., Ahaghotu C., Sutherland D.P., Fortuno E.S., III, Kollmann T.R., Demos M., Friedman J.M., Speert D.P., Gahl W.A., and Boerkoel C.F. 2013. Recurrent subacute post-viral onset of ataxia associated with a PRF1 mutation. Eur. J. Hum. Genet. 21:1232–1239.
Dudkina N.V., Spicer B.A., Reboul C.F., Conroy P.J., Lukoyanova N., Elmlund H., Law R.H., Ekkel S.M., Kondos S.C., Goode R.J., Ramm G., Whisstock J.C., Saibil H.R., and Dunstone M.A. 2016. Structure of the poly-C9 component of the complement membrane attack complex. Nat. Commun. 7:10588.
Fernie B.A., Orren A., Sheehan G., Schlesinger M., and Hobart M.J. 1997. Molecular bases of C7 deficiency: Three different defects. J. Immunol. 159(2):1019–1026.
Gao L., Dang X., Huang L., Zhu L., Fang M., Zhang J., Xu X., Li T., Zhao L., Wei J., and Zhou J. 2016. Search for the potential “second-hit” mechanism underlying the onset of familial hemophagocytic lymphohistiocytosis type 2 by whole-exome sequencing analysis. Transl. Res. 170:26–39.
Gilbert R.J., Mikelj M., Dalla Serra M., Froelich C.J., and Anderluh G. 2013. Effects of MACPF/CDC proteins on lipid membranes. Cell Mol. Life Sci. 70(12):2083–2098.
Grossman W.J., Radhi M., Schauer D., Gerday E., Grose C., and Goldman F.D. 2005. Development of hemophagocytic lymphohistiocytosis in triplets infected with HHV-8. Blood. 106(4):1203–1206.
Guerois R., Nielsen J.E., and Serrano L. 2002. Predicting changes in the stability of proteins and protein complexes: A study of more than 1000 mutations. J. Mol. Biol. 320(2):369–387.
Henter J.I., Horne A., Arico M., Egeler R.M., Filipovich A.H., Imashuku S., Ladisch S., McClain K., Webb D., Winiarski J., and Janka G. 2007. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer. 48(2):124–131.
Huang Z., Wang Y., Xie Z., and Shen K. 2014. Remission and relapse of hemophagocytic lymphohistiocytosis in a patient harboring a PRF1 homozygous mutation: A case report. J. Pediatr. Hematol. Oncol. 36(1):e5–e8.
Imashuku S. 2014. Hemophagocytic lymphohistiocytosis: Recent progress in the pathogenesis, diagnosis and treatment. World J. Hematol. 3(3):14.
Janka G.E. 2012. Familial and acquired hemophagocytic lymphohistiocytosis. Annu. Rev. Med. 63:233–246.
Krieger E. and Vriend G. 2014. YASARA View—Molecular graphics for all devices—From smartphones to workstations. Bioinformatics. 30(20):2981–2982.
Law R.H., Lukoyanova N., Voskoboinik I., Caradoc-Davies T.T., Baran K., Dunstone M.A., D’Angelo M.E., Orlova E.V., Coulibaly F., Verschoor S., Browne K.A., Ciccone A., Kuiper M.J., Bird P.I., Trapani J.A., Saibil H.R., and Whisstock J.C. 2010. The structural basis for membrane binding and pore formation by lymphocyte perforin. Nature. 468(7322):447–451.
Lukoyanova N., Hoogenboom B.W., and Saibil H.R. 2016. The membrane attack complex, perforin and cholesterol-dependent cytolysin superfamily of pore-forming proteins. J. Cell Sci. 129(11):2125–2133.
Mancebo E., Allende L.M., Guzman M., Paz-Artal E., Gil J., Urrea-Moreno R., Fernandez-Cruz E., Gaya A., Calvo J., Arbos A., Duran M.A., Canet R., Balanzat J., Udina M.A., and Vercher F.J. 2006. Familial hemophagocytic lymphohistiocytosis in an adult patient homozygous for A91V in the perforin gene, with tuberculosis infection. Haematologica. 91(9):1257–1260.
McKeone R., Wikstrom M., Kiel C., and Rakoczy P.E. 2014. Assessing the correlation between mutant rhodopsin stability and the severity of retinitis pigmentosa. Mol. Vis. 20:183–199.
Mellor-Heineke, S., Villanueva, J., Jordan, M.B., Marsh, R., Zhang, K., Bleesing, J.J., Filipovich, A.H., and Risma, K.A. 2013. Elevated granzyme B in cytotoxic lymphocytes is a signature of immune activation in hemophagocytic lymphohistiocytosis. Front. Immunol. 472.
Mhatre S., Madkaikar M., Jijina F., and Ghosh K. 2014. Unusual clinical presentations of familial hemophagocytic lymphohistiocytosis type-2. J. Pediatr. Hematol. Oncol. 36(8):e524–e527.
Molleran Lee S., Villanueva J., Sumegi J., Zhang K., Kogawa K., Davis J., and Filipovich A.H. 2004. Characterisation of diverse PRF1 mutations leading to decreased natural killer cell activity in North American families with haemophagocytic lymphohistiocytosis. J. Med. Genet. 41(2):137–144.
Nagafuji K., Nonami A., Kumano T., Kikushige Y., Yoshimoto G., Takenaka K., Shimoda K., Ohga S., Yasukawa M., Horiuchi H., Ishii E., and Harada M. 2007. Perforin gene mutations in adult-onset hemophagocytic lymphohistiocytosis. Haematologica. 92(7):978–981.
Pey A.L., Stricher F., Serrano L., and Martinez A. 2007. Predicted effects of missense mutations on native-state stability account for phenotypic outcome in phenylketonuria, a paradigm of misfolding diseases. Am. J. Hum. Genet. 81(5):1006–1024.
Ramachandran R., Tweten R.K., and Johnson A.E. 2004. Membrane-dependent conformational changes initiate cholesterol-dependent cytolysin oligomerization and intersubunit beta-strand alignment. Nat. Struct. Mol. Biol. 11(8):697–705.
Rameix-Welti M.A., Regnier C.H., Bienaime F., Blouin J., Schifferli J., Fridman W.H., Sautes-Fridman C., and Fremeaux-Bacchi V. 2007. Hereditary complement C7 deficiency in nine families: Subtotal C7 deficiency revisited. Eur. J. Immunol. 37(5):1377–1385.
Risma K.A., Frayer R.W., Filipovich A.H., and Sumegi J. 2006. Aberrant maturation of mutant perforin underlies the clinical diversity of hemophagocytic lymphohistiocytosis. J. Clin. Invest. 116(1):182–192.
Rosado C.J., Buckle A.M., Law R.H., Butcher R.E., Kan W.T., Bird C.H., Ung K., Browne K.A., Baran K., Bashtannyk-Puhalovich T.A., Faux N.G., Wong W., Porter C.J., Pike R.N., Ellisdon A.M., Pearce M.C., Bottomley S.P., Emsley J., Smith A.I., Rossjohn J., Hartland E.L., Voskoboinik I., Trapani J.A., Bird P.I., Dunstone M.A., and Whisstock J.C. 2007. A common fold mediates vertebrate defense and bacterial attack. Science. 317(5844):1548–1551.
Sanchez I.P., Leal-Esteban L.C., Alvarez-Alvarez J.A., Perez-Romero C.A., Orrego J.C., Serna M.L., Coll Y., Caicedo Y., Pardo-Diaz E., Zimmer J., Bleesing J.J., Franco J.L., and Trujillo-Vargas C.M. 2012. Analyses of the PRF1 gene in individuals with hemophagocytic lymphohystiocytosis reveal the common haplotype R54C/A91V in Colombian unrelated families associated with late onset disease. J. Clin. Immunol. 32(4):670–680.
Sieni E., Cetica V., Hackmann Y., Coniglio M.L., Da Ros M., Ciambotti B., Pende D., Griffiths G., and Arico M. 2014. Familial hemophagocytic lymphohistiocytosis: When rare diseases shed light on immune system functioning. Front. Immunol. 5:167.
Sieni E., Cetica V., Piccin A., Gherlinzoni F., Sasso F.C., Rabusin M., Attard L., Bosi A., Pende D., Moretta L., and Arico M. 2012. Familial hemophagocytic lymphohistiocytosis may present during adulthood: Clinical and genetic features of a small series. PLoS ONE. 7(9):e44649.
Stefl S., Nishi H., Petukh M., Panchenko A.R., and Alexov E. 2013. Molecular mechanisms of disease-causing missense mutations. J. Mol. Biol. 425(21):3919–3936.
Stepp S.E., Dufourcq-Lagelouse R., Le Deist F., Bhawan S., Certain S., Mathew P.A., Henter J.I., Bennett M., Fischer A., de Saint Basile G., and Kumar V. 1999. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 286(5446):1957–1959.
Stewart S.E., Bird C.H., Tabor R.F., D’Angelo M.E., Piantavigna S., Whisstock J.C., Trapani J.A., Martin L.L., and Bird P.I. 2015. Analysis of perforin assembly by quartz crystal microbalance reveals a role for cholesterol and calcium-independent membrane binding. J. Biol. Chem. 290(52):31101–31112.
Tesi B., Chiang S.C., El-Ghoneimy D., Hussein A.A., Langenskiold C., Wali R., Fadoo Z., Silva J.P., Lecumberri R., Unal S., Nordenskjold M., Bryceson Y.T., Henter J.I., and Meeths M. 2015. Spectrum of atypical clinical presentations in patients with biallelic PRF1 missense mutations. Pediatr. Blood Cancer. 62(12):2094–2100.
Thiery J. and Lieberman J. 2014. Perforin: A key pore-forming protein for immune control of viruses and cancer. Subcell Biochem. 80197–80220.
Tokuriki N. and Tawfik D.S. 2009. Stability effects of mutations and protein evolvability. Curr. Opin. Struct. Biol. 19(5):596–604.
Tokuriki N., Stricher F., Serrano L., and Tawfik D.S. 2008. How protein stability and new functions trade off. PLoS Comput. Biol. 4(2):e1000002.
Ueda I., Kurokawa Y., Koike K., Ito S., Sakata A., Matsumora T., Fukushima T., Morimoto A., Ishii E., and Imashuku S. 2007. Late-onset cases of familial hemophagocytic lymphohistiocytosis with missense perforin gene mutations. Am. J. Hematol. 82(6):427–432.
Urrea Moreno R., Gil J., Rodriguez-Sainz C., Cela E., LaFay V., Oloizia B., Herr A.B., Sumegi J., Jordan M.B., and Risma K.A. 2009. Functional assessment of perforin C2 domain mutations illustrates the critical role for calcium-dependent lipid binding in perforin cytotoxic function. Blood. 113(2):338–346.
Voskoboinik I., Dunstone M.A., Baran K., Whisstock J.C., and Trapani J.A. 2010. Perforin: Structure, function, and role in human immunopathology. Immunol. Rev. 235(1):35–54.
Voskoboinik I., Whisstock J.C., and Trapani J.A. 2015. Perforin and granzymes: Function, dysfunction and human pathology. Nat. Rev. Immunol. 15(6):388–400.
Wang Y., Wang Z., Chen H., and Wang X. 2012. Adult onset of primary hemophagocytic syndrome in subjects carrying PRF1 mutations. Ann. Hematol. 91:1489–1490.
Wang Z. and Moult J. 2001. SNPs, protein structure, and disease. Hum. Mutat. 17(4):263–270.
Worth C.L., Preissner R., and Blundell T.L. 2011. SDM—A server for predicting effects of mutations on protein stability and malfunction. Nucleic Acids Res. 39(Web Server issue):W215–W222.
Yagi H., Conroy P.J., Leung E.W., Law R.H., Trapani J.A., Voskoboinik I., Whisstock J.C., and Norton R.S. 2015. Structural basis for Ca2+-mediated interaction of the Perforin C2 Domain with Lipid membranes. J. Biol. Chem. 290(42):25213–25226.
Yin S., Ding F., and Dokholyan N.V. 2007. Eris: An automated estimator of protein stability. Nat. Methods. 4(6):466–467.
Yue P., Li Z., and Moult J. 2005. Loss of protein structure stability as a major causative factor in monogenic disease. J. Mol. Biol. 353(2):459–473.
Zhang K., Jordan M.B., Marsh R.A., Johnson J.A., Kissell D., Meller J., Villanueva J., Risma K.A., Wei Q., Klein P.S., and Filipovich A.H. 2011. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood. 118(22):5794–5798.
Zur Stadt U., Beutel K., Kolberg S., Schneppenheim R., Kabisch H., Janka G., and Hennies H.C. 2006. Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: Molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A. Hum. Mutat. 27(1):62–68.
Information & Authors
Information
Published In
LymphoSign Journal
Volume 4 • Number 3 • September 2017
Pages: 101 - 112
History
Received: 23 May 2017
Accepted: 27 July 2017
Accepted manuscript online: 3 August 2017
Copyright
© 2017.
Authors
Competing Interests
The authors declare no conflict of interest.
Funding Information
This work was supported by a grant from the Spanish NIH (ISCIII FIS PI12/02761).
Metrics & Citations
Metrics
Other Metrics
Citations
Cite As
RamónUrrea Moreno, ItziarAstigarraga, AnaFernández-Teijeiro, CarmenRodríguez-Sainz, MaríaAlonso-Martinez, LydiaMartín-Martín, SusanaGarcía-Obregón, and JuanaGil-Herrera. 2017. The novel p.Gly306Asp perforin mutation causes familial hemophagocytic lymphohistiocytosis type 2 (FHL-2) probably due to a critical role of Gly306 in the pore-forming perforin domain. LymphoSign Journal.
4(3): 101-112. https://doi.org/10.14785/lymphosign-2017-0006
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
There are no citations for this item
View Options
Login options
Check if you access through your login credentials or your institution to get full access on this article.
